Starting July 1, Medicare will cover GLP-1 obesity drugs like Wegovy, opening up access for millions of seniors who previously couldn't afford them.
Posts published in “GLP-1”
Researchers are working on new formulations of GLP-1 drugs that could reduce how often patients need to take them — potentially shifting from weekly injections to just once a quarter.
A psychological phenomenon called "ghost fat" is being reported among people who've lost significant weight on GLP-1 drugs — they continue to see themselves as overweight even after the pounds are gone, similar to body dysmorphia.
A large observational study found that breast cancer patients who took GLP-1 drugs had better survival outcomes compared to those who didn't. Researchers say the findings are promising but call for formal clinical trials to confirm whether the drugs are actually responsible for the benefit.
A therapist who specializes in eating disorders addresses the complicated pull that GLP-1 weight-loss drugs can have for people already struggling with their relationship with food.
A new at-home genetic test called MyPhenome claims it can tell you whether your body is likely to respond to GLP-1 weight-loss drugs before you spend thousands of dollars on them.
A new study found that people taking GLP-1 weight-loss drugs became less physically active over time — daily steps dropped from about 5,047 to 4,487, and moderate exercise fell from 28 to 22 minutes per day.
As GLP-1 drugs like Wegovy become more popular, employers are under growing financial pressure and some are reconsidering whether to cover them for weight loss at all.